Debiopharm files new Trelstar formulation in US
This article was originally published in Scrip
Executive Summary
Debiopharm has filed an NDA with the US FDAfor its six-month sustained-release formulation of Trelstar (triptorelin pamoate) for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. If approved, Trelstar will be marketed in the US by Watson Pharmaceuticals.